Results 81 to 90 of about 2,377 (150)

Siponimod As a Novel Inhibitor of Retinal Angiogenesis: In Vitro and In Vivo Evidence of Therapeutic Efficacy

, 2023
Sphingosine-1-phosphate (S1P) receptors control endothelial cell proliferation, migration, and survival. Evidence of the ability of S1P receptor modulators to influence multiple endothelial cell functions suggests their potential use for antiangiogenic ...
Rania Gamal Eldin Zaki, Alshaikh, Rasha A., Waeber, Christian, Rasha A. Alshaikh, Gamal Eldin Zaki, Rania, Salah El Din, Rania A., Rania A. Salah El Din, Christian Waeber, Ryan, Katie B., Katie B. Ryan   +9 more
core   +1 more source

Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen, Zhenyu Niu, Ting Yang, Xuanling Zhang, Ran Wei, Xiaocong Pang, Ran Liu, Ying Zhou   +7 more
wiley   +1 more source

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis

Frontiers in Pharmacology
BackgroundSiponimod, a second-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, represents an important therapeutic choice for active secondary progressive multiple sclerosis (SPMS).
Victor Constantinescu, Victor Constantinescu, Rocco Haase, Katja Akgün, Tjalf Ziemssen   +4 more
doaj   +1 more source

EFFECTS OF SIPONIMOD (BAF312) ON SYNAPTIC NEURODEGENERATIVE DAMAGE IN EXPERIMENTAL MULTIPLE SCLEROSIS [PDF]

, 2016
Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative damage causing irreversible disability in these disorders.
Bullitta, Silvia, Piras, Eleanora, Centonze, Diego, Mandolesi, Georgia, De Vito, Francesca, Schubart Wellensiek, Anna, Gargano, Francesca, Gentile, Antonietta, Fresegna, Diego, Musella, Alessandra, Battistini, Luca, Borsellino, Giovanna   +11 more
core  

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series

, 2022
Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has recently been marketed for patients with Secondary Progressive Multiple Sclerosis (SPMS).
Floriana Bile, Miele, Giuseppina, Lavorgna, Luigi, Bile, Floriana, Bonavita, Simona, Giuseppina Miele, Simona Bonavita, Abbadessa, Gianmarco, Elisabetta Maida, Maida, Elisabetta, Gianmarco Abbadessa, Luigi Lavorgna   +11 more
core   +1 more source

Table1_Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials.pdf

, 2022
Objectives: This study aimed to investigate the pharmacokinetic characteristics of siponimod in healthy volunteers and patients with MS based on aggregated data from published clinical trials, and to explore the factors influencing siponimod exposure ...
Ma Lingyun (12521032), Cui Yimin (12521044), Chen Chaoyang (12521026), Wei Ran (423943), Zhang Enyao (12521041), Dong Xiu (12521029), Li Ruoming (12521038), Zhao Simiao (12521035), Liu Zhenming (12521047), Zhou Ying (8859572)   +9 more
core   +1 more source

Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury

Glaucoma is a leading cause of permanent blindness worldwide and is characterized by neurodegeneration linked to progressive retinal ganglion cell (RGC) death, axonal damage, and neuroinflammation.
Vander Wall, Roshana, Mirzaei, Mehdi, Chitranshi, Nitin, You, Yuyi, Basavarajappa, Devaraj, Viswanathan, Deepa, Klistorner, Alexander, Gupta, Veer, Palanivel, Viswanthram, Gupta, Vivek, Graham, Stuart L   +10 more
core   +1 more source

Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage

, 2019
Background and Purpose- Perihemorrhagic edema (PHE) is associated with poor outcome after intracerebral hemorrhage (ICH). Infiltration of immune cells is considered a major contributor of PHE.
Schwab, Stefan, Bäuerle, Tobias, Engelhorn, Tobias, Roeder, Sebastian S., Burkardt, Petra, Horsten, S.v., Nagel, Armin M., Bobinger, Tobias, Linker, Ralf A., Huttner, Hagen B., Seyler, Lisa, Beuscher, Vanessa, Manaenko, Anatol, Sprügel, Maximilian I., Dörfler, Arnd   +14 more
core   +1 more source

Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

, 2018
Siponimod, a next generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis.
Glaenzel, Ulrike, Li, Wenkui, Nufer, Robert, Hubert Borell, Yi Jin, Jin, Yi, Kirsten Schroer, Alexander D. James, Gardin, Anne, Legangneux, Eric, Axel Meissner, Sylvie Adam-Stitah, Borell, Hubert, Wenkui Li, Sjoerd Peter van Marle, Meissner, Axel, Ulrike Glaenzel, Gian Camenisch, James, Alexander David, Robert Nufer, Adam, Sylvie, van Marle, Sjoerd Peter, Anne Gardin, Schroer, Kirsten, Eric Legangneux, Camenisch, Gian P.   +25 more
core   +1 more source

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.

, 2013
Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to washout in 7 days.
Selmaj, K;Li, DK;Hartung, HP;Hemmer, B;Kappos, L;Freedman, MS;Stüve, O;Rieckmann, P;Montalban, X;Ziemssen, T;Auberson, LZ;Pohlmann, H;Mercier, F;Dahlke, F;Wallstrom, E
core   +1 more source